Pneumovax 23 0,5 mL Solution for Injection
PDF Leaflet Revision Date: 16 July 2020
Clinical Summary
Quick overview from the medicine insert
Indication
Vaccination against pneumococcal disease for high-risk individuals from 2 years of age.
Dosage (summary)
Administer a single 0.5 mL dose subcutaneously or intramuscularly.
Onset of Action / Duration
Onset: 3 weeks, Duration: 5-10 years
Special Populations
- Elderly patients (u2265 65 years)
- Immunocompromised patients
- Chronic illness patients
Pregnancy & Breastfeeding
Safety in pregnancy and lactation not established.
Key Drug Interactions
- Influenza vaccine (administer separately)
- ZOSTAVAX (do not administer concurrently)
Contraindications
- Hypersensitivity to vaccine components
- Children < 2 years
Common side effects
- Injection site reactions
- Fever
- Fatigue
- Myalgia
- Headache
Counselling Points
- Inform about potential side effects
- Advise on the importance of vaccination timing
- Ensure adrenaline is available for anaphylactic reactions
Serious warnings
- Risk of febrile reaction with concurrent endotoxin vaccines
- Caution in patients with compromised cardiovascular/pulmonary function
Important Disclaimer
The Pneumovax 23 0,5 mL Solution for Injection professional information leaflet below is the property of Msd and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
